technology
PushButton AI Team ·
Roche just paid $750M for an AI tool that does one specific thing really well. Not everything. One thing. That's the lesson most business owners miss when they're staring down a wall of AI options f
Roche just paid $750M for an AI tool that does one specific thing really well.
Not everything. One thing.
That's the lesson most business owners miss when they're staring down a wall of AI options feeling completely lost.
You're not alone in buying that AI subscription that's collecting dust. Smart people get burned by tools that promised everything and delivered confusion. That's not a failure of your judgment — it's a failure of how AI gets sold.
Here's what the Roche deal quietly reveals: the companies winning with AI right now didn't adopt AI broadly. They identified one painful, repetitive problem — in Roche's case, reading pathology slides — and found a tool built specifically for that problem.
That's the opposite of what most AI vendors pitch you. They sell platforms. Winners buy solutions to specific problems.
Your action this week: write down the one task in your business that is repetitive, high-volume, and currently eating someone's time. Just one. That's your starting point — not a strategy overhaul, not a new hire.
One problem. One tool. Thirty days to prove it works.
What's the one task in your business you wish someone — or something — could take off your plate right now?
#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation
Roche acquires PathAI for $750M to integrate AI pathology tools into its diagnostics division and clinical trial infrastructure for oncology drug ...
